Established in June 2011 and incubated at TLS since January 2012, the company was founded as a spin-off of HansaBioMed OU for the exploitation of the EXOTESTTM technology platform, in order to evolve it in the sense of multiplexing, and to validate a wide panel of biomarkers to diagnose and predict cancer on it. In particular, the company’s aim is to develop and validate new immunometric assays for the diagnosis of cancer based on exosomal biomarkers (proteins and RNA) to bring to market.
The laboratories of Exosomics Siena are located at the Medicines Research Center of Toscana Life Sciences, where eight highly qualified and experienced researchers work. The company has a qualified management team that manages both the operational and scientific aspects as well as strategic alliances and business development.
Exosomics Siena collaborates with several research groups at the national and international levels for the development of the technologies and assays described above, including the Italian National Institute of Health, the University of Siena, Local Health Authority 12 in Venice, Harvard University, Yale University, the University of Riga and the Karolinska Institute in Stockholm. Exosomics Siena and its parent company HansaBioMed are global leaders in the field of exosome diagnostics, with more know-how and intellectual property in the field than any other academic or industrial group in the world.